Waystar Holding Corp. Stock Price, News & Analysis

RIS Rx (WAY) appointed John Driscoll as Chairman of the Board effective October 15, 2025. Driscoll is a veteran healthcare executive with leadership roles across payers, providers, and health‑tech platforms, including Executive Vice President and President, U.S. Healthcare at Walgreens Boots Alliance, nearly a decade as CEO of CareCentrix, and earlier roles at Castlight Health and Medco. He currently serves as Independent Chairman at Waystar (Nasdaq: WAY) and chairs the boards of UConn Health and Magnit Global. Management says Driscoll’s experience in scaling care‑at‑home and healthcare payment technology will support RIS Rx’s expansion and efforts to ensure patient financial support reaches patients.

Waystar (Nasdaq: WAY) will report third-quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, October 29, 2025 after market close. The company will host a conference call at 4:30 p.m. Eastern Time the same day and provide a live audio webcast accessible from its investor relations website.

The webcast will be archived on the investor site for later access by investors and analysts.

Waystar (NASDAQ:WAY) has successfully completed its acquisition of Iodine Software, a strategic move that combines one of the industry's largest financial datasets with one of the largest clinical datasets. The acquisition expands Waystar's total addressable market by over 15% by adding Iodine's client base of more than 1,000 hospitals and health systems.

The deal is expected to be immediately accretive to gross margin and adjusted EBITDA margin, with positive impacts on revenue growth and non-GAAP net income per diluted share anticipated by 2027. The combination strengthens Waystar's AI-powered platform by integrating comprehensive clinical and financial intelligence, enhancing automation in healthcare revenue cycle management.

Waystar Holding Corp. (Nasdaq: WAY), a healthcare payment software provider, has been added to the S&P SmallCap 600® Index effective September 22, 2025. The company's platform serves over one million providers and processes more than $1.8 trillion in gross claims annually.

The company has demonstrated strong performance metrics, including a 115% net revenue retention and up to 15% year-over-year growth in scaled clients. Their AI innovation, Waystar AltitudeAI™, has shown significant results, accelerating denial appeals 3x faster and improving overturn rates by over 40%.

Waystar (Nasdaq: WAY) unveiled significant AI-powered innovations at its Fall Innovation Showcase to address major healthcare payment challenges. The company's AltitudeAI platform targets three critical issues: $20 billion in denial recovery costs, $17 billion in uncompensated care, and $2.6 billion in manual payer reimbursement inefficiencies.

The platform demonstrates impressive results, including 90% time savings across key capabilities, 40% more denial overturns for early adopters, and an increase in pre-service patient payments from 17% to 40%. For mid-size health systems, the solution reduces denial appeal processing time from 38 hours to 2 hours and cuts denial prevention work from 133 hours to under 6 hours.

EQT has completed a significant public offering of Waystar Holding Corp. (NASDAQ: WAY) common stock. The offering involved approximately 18.0 million shares, generating total proceeds of $705.8 million for all selling stockholders. EQT sold about 7.8 million shares for proceeds of $304.5 million, retaining approximately 24.9 million shares after the transaction.

The offering, underwritten by J.P. Morgan Securities LLC, was completed on September 12, 2025. Notably, Waystar Holding Corp. did not sell any shares in this offering and received no proceeds from the transaction.

Waystar (NASDAQ: WAY), a healthcare payments software provider, has announced the pricing of a secondary offering where existing shareholders will sell 18 million shares at $39.40 per share. The selling stockholders include investment funds from EQT AB, Bain Capital, LP, and Canada Pension Plan Investment Board.

The offering is expected to close around September 12, 2025, with J.P. Morgan acting as the underwriter. Importantly, Waystar will not receive any proceeds from this secondary offering as the company is not selling any shares directly.

Waystar (NASDAQ: WAY), a healthcare payments software provider, has announced a secondary offering of 18 million shares of common stock. The offering is being conducted by existing shareholders including EQT AB, Bain Capital, and CPP Investments (the Selling Stockholders).

J.P. Morgan will serve as the underwriter for the offering, which will be made through a registration statement filed with the SEC. Importantly, Waystar will not receive any proceeds from this secondary offering as the company is not selling any shares directly.

Waystar (Nasdaq: WAY), a healthcare payment software provider, has been named to Fast Company's 2025 Best Workplaces for Innovators in North America list. The company's cloud-based, AI-powered platform serves over 1 million providers and recently launched Waystar AltitudeAI™, focusing on claim denial prevention and recovery.

The recognition follows other notable accolades, including Forbes' Most Trusted Company in America, Fortune's Best Workplace in Health Care, and KLAS Research's Best in KLAS software platform awards. Waystar plans to showcase its latest innovations at its Fall Innovation Showcase during the annual Waystar True North™ client conference on September 16, 2025.